Pregledni rad

Effects of Tamoxifen on the female genital tract

Mario Puljiz ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
Damir Danolić ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
Ilija Alvir ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia
Ivica Mamić ; Department of Gynecologic Oncology, University Hospital for Tumors, Sestre Milosrdnice University Hospital Centre, Zagreb, Croatia

Sažetak

Tamoxifen, a triphenylethyleneestrogen receptor modulator, is an eff ective treatment for estrogen receptor positive breast cancer patients. It acts as an estrogen antagonist in breast tissue and a week estrogen agonist in the female genital tract. Its estrogenagonist properties refl ects on increased risk of gynaecologic pathologies and includes the development of
endometrial cancer, endometrial hyperplasia, endometrial polyps, adenomyosis, leiomyomas, uterine sarcomas, cervical polyps and ovarian cysts. Breast cancer patients during tamoxifen treatment should be under close gynaecological and ultrasonographic surveillance.

Ključne riječi

tamoxifen; breast cancer; female genital tract; endometrial cancer

Hrčak ID:

199080

URI

https://hrcak.srce.hr/199080

Datum izdavanja:

29.12.2014.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.999 *